Acumen Pharmaceuticals (ABOS) Accumulated Expenses (2020 - 2026)

Acumen Pharmaceuticals has reported Accumulated Expenses for 7 years, with the latest figure at $5.3 million in Q1 2026.

• Quarterly Accumulated Expenses fell 21.5% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 21.5% YoY) and the FY2025 annual result came in at $10.1 million, up 52.26% from the prior year.
• Accumulated Expenses declined to $5.3 million in Q1 2026 per ABOS's latest filing, from $10.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.6 million in Q2 2025 and troughed at $2.4 million in Q2 2023.
• A 5-year average of $5.2 million and a median of $4.4 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 297.11% in 2022, then declined 27.93% in 2023.
• Over 5 years, Accumulated Expenses stood at $3.4 million in 2022, then jumped by 92.51% to $6.4 million in 2023, then increased by 2.57% to $6.6 million in 2024, then soared by 52.26% to $10.1 million in 2025, then sank by 47.7% to $5.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.3 million, $10.1 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.